Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3423-3428

  Zhang, Wei ^a   Yang, Hsin Chih ^a   Wang, Qi ^a   Yang, Zhi Jun ^a   Chen, Hong ^a   Wang, Su Mei ^a   Pan, Zhong Mian ^a   Tang, Bu Jian ^a   Li, Qingdi Quentin ^b   Li, Li ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Biomarkers; Cathepsin; Diagnosis; Enzyme linked immunosorbent assay; Heparanase; Matrix metalloproteinase 9; Ovarian cancer

Indexed keywords

CATHEPSIN L; GELATINASE B; HEPARANASE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER INVASION; CANCER PATIENT; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GERM CELL TUMOR; GOLD STANDARD; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MUCOUS CYSTIC ADENOCARCINOMA; MUCOUS CYSTIC ADENOMA; NON DIFFERENTIATED CARCINOMA; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PERITONEUM METASTASIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROUS CYSTIC ADENOCARCINOMA; SEROUS CYSTIC ADENOMA; SEX CORD TUMOR; TERATOMA;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CATHEPSIN L; FEMALE; GLUCURONIDASE; HUMANS; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80054723111     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Deraco M, Baratti D and Laterza B: Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol 37: 4-9, 2011.
2. Johnatty SE, Beesley J and Paul J: ABCB1 (MDR1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 14: 5594-5601, 2008.
3. Chua TC, Liauw W and Robertson G: Second-line treatment of first relapse recurrent ovarian cancer. Aust N Z J Obstet Gynaecol 50: 465-471, 2010.
4. Westermarck J and Kahari V-M: Regulation of matrix metalloproteinase expression in tumour invasion. FASEB J 13: 781-792, 1999. (Pubitemid 29220691)
5. Nishikawa H, Ozaki Y and Nakanishi T: The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol 92: 881-886, 2004. (Pubitemid 38251392)
6. Peretz T, Antebi SU and Beller U: Maintenance on extracellular matrix and expression of heparanase activity by human ovarian carcinoma cells from biopsy specimens. Int J Cancer 45: 1054-1060, 1990. (Pubitemid 20201575)
7. Vihinen P and Kahari VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99: 157-166, 2002. (Pubitemid 34309470)
8. Kim TD, Song KS and Li G: Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 6: 211-221, 2006.
9. Papathoma AS, Petraki C and Grigorakis A: Prognostic significance of matrix metalloproteinase-2 and -9 in bladder cancer. Anticancer Res 20: 2009-2013, 2000. (Pubitemid 30636174)
10. Wang GB, Zhou XY and Wang XQ: Relationship between serum heparanase and microscopic venous invasion in patients with hepatocellular carcinoma. Am J Clin Pathol 134: 242-248, 2010.
11. Theodoro TR, de Matos LL and Sant Anna AV: Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Neoplasia 9: 504-510, 2007. (Pubitemid 46983453)
12. Naumnik W, Niklińska W and Ossolińska M: Serum cathepsin K and cystatin C concentration in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol 47: 207-213, 2009.
13. Rauvala M, Aglund K and Puistola U: Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression. Int J Gynecol Cancer 16: 1297-1302, 2006. (Pubitemid 43886760)
14. Määttä M, Santala M and Soini Y: Matrix metalloproteinases-2 and -9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumour Biol 25: 188-192, 2004. (Pubitemid 39551745)
15. Bran JL, Cortez A, Commo F and Uzan S: Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol 33: 1239-1246, 2008.
16. Ozalp S, Tanir HM and Yalcin OT: Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol 24: 1417-1420, 2003.
17. Nishikawa H, Ozaki Y and Nakanishi T: The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol 92: 881-886, 2004. (Pubitemid 38251392)
18. Somiari SB, Somiari RI and Heckman CM: Circulating MMP-2 and MMP-9 in breast cancer potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 119: 1403-1411, 2006. (Pubitemid 44258818)
19. Hurst NG, Stocken DD and Wilson S: Elevated serum matrix metalloproteinase-9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 97: 971-977, 2007. (Pubitemid 47519304)
20. Wu ZS, Wu Q and Yang JH: Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122: 2050-2056, 2008. (Pubitemid 351441195)
21. Manenti L, Paganoni P and Floriani I: Expression levels of vascular endothelial growth factor, matrix metalloproteinases-2 and -9 and tissue inhibitor of metalloproteinases-1 and -2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 39: 1948-1956, 2003. (Pubitemid 37311193)
22. Downs LS, Lima PH and Bliss RL: Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer. J Soc Gynecol Investig 12: 539-544, 2005. (Pubitemid 41395244)
23. Fata JE, Ho AT and Leco KJ: Cellular turnover and extracellular matrix remodeling in female reproductive tissues: functions of metalloproteinases and their inhibitors. Cell Mol Life Sci 57: 77-95, 2000. (Pubitemid 30105331)
24. Shield K, Ackland ML and Ahmed N: Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol 113: 143-148, 2009.
25. Karihtala P, Mäenpää J and Turpeenniemi-Hujanen T: Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial. Anticancer Res 30: 1001-1006, 2010.
26. Shinyo Y, Kodama J and Hongo A: Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Annals of Oncol 14: 1505-1510, 2003. (Pubitemid 37304605)
27. Siewinski M, Saleh Y and Gryboc M: Determination of cysteine peptidase-like activity and their inhibitors in the serum of patients with ovarian cancer treated by conventional chemotherapy and vitamin E. J Exp Ther Oncol 4: 189-193, 2004. (Pubitemid 39557169)
28. Wang S, Li L and Zhang W: The clinical value of serum cathepsin L on diagnosis and monitoring of ovarian cancer. Zhongguo Zhongliu Linchuang 35: 167-168, 2008.
29. Yurkovetsky Z, Skates S and Lomakin A: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28: 2159-2166, 2010.
30. Sakata K, Shigemasa K and Nagai N: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1,TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17: 673-681, 2000.
31. Zhongxian W, Shaoyang L and Daqiong J: The expression and significance of cathepsins in ovarian cancer tissues. Zhongliu 26: 559-562, 2006.
32. Kodama J, Shinyo Y and Hashen G: Heparanase messenger RNA expression in epithelial ovarian tumor. Int J Mol Med 12: 961-964, 2003.
33. Wang M, Tang J and Liu S: Expression of cathepsinB and microvascular density increases with higher grade of astrocytomas. J Neurooncol 71: 3-7, 2005. (Pubitemid 40277246)
34. He X, Brenchley PE and Janyson GC: Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res 64: 3928-3933, 2004. (Pubitemid 38697306)
35. Ricciardelli C and Rodgers RJ: Extracellular matrix of ovarian tumors. Semin Reprod Med 24: 270-282, 2006. (Pubitemid 44389345)